Stoke Therapeutics Inc. (STOK): Price and Financial Metrics

Stoke Therapeutics Inc. (STOK): $12.09

-0.34 (-2.74%)

POWR Rating

Component Grades













Add STOK to Watchlist
Sign Up

Industry: Biotech



in industry

STOK Stock Price Chart Interactive Chart >

Price chart for STOK

STOK Price/Volume Stats

Current price $12.09 52-week high $41.60
Prev. close $12.43 52-week low $11.93
Day low $11.93 Volume 137,200
Day high $12.50 Avg. volume 321,401
50-day MA $18.57 Dividend yield N/A
200-day MA $21.69 Market Cap 473.25M

Stoke Therapeutics Inc. (STOK) Company Bio

Stoke Therapeutics, Inc. was founded in 2014 by Professor Adrian Krainer, PhD. and Isabel Aznarez, PhD to research and develop treatments for the underlying cause of genetic diseases. The company focuses on developing antisense oligonucleotide medicines that increase gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver, and kidney. Stoke’s proprietary platform, Targeted Augmentation of Nuclear Gene Output (TANGO) allows for the delivery of disease-modifying therapies in a precise and controlled manner. Edward M. Kaye, M.D., currently serves as the company’s director and Chief Executive Officer.

STOK Latest News Stream

Event/Time News Detail
Loading, please wait...

STOK Latest Social Stream

Loading social stream, please wait...

View Full STOK Social Stream

Latest STOK News From Around the Web

Below are the latest news stories about Stoke Therapeutics Inc that investors may wish to consider to help them evaluate STOK as an investment opportunity.

Wall Street Analysts See a 192% Upside in Stoke Therapeutics, Inc. (STOK): Can the Stock Really Move This High?

The consensus price target hints at a 192.2% upside potential for Stoke Therapeutics, Inc. (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | February 10, 2022

Stoke Therapeutics initiated Buy at Jefferies on potential of RNA therapy platform

Stoke Therapeutics <> is trading higher after Jefferies launched its coverage with a Buy recommendation noting the prospects of its proprietary ribonucleic acid ((RNA))

Seeking Alpha | January 31, 2022

Stoke Therapeutics (STOK) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference

No summary available.

Seeking Alpha | January 24, 2022

Acadia (ACAD) Up More Than 20% in Past 3 Months: Here's Why

Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, has seen strong uptake so far. Its label expansion studies also hold promise.

Yahoo | January 13, 2022

Analysts’ Top Healthcare Picks: Exact Sciences (EXAS), BioAtla (BCAB)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Exact Sciences (EXAS – Research Report), BioAtla (BCAB – Research Report) and Stoke Therapeutics (STOK – Research Report) with bullish sentiments. Exact Sciences (EXAS) In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Exact Sciences, with a price target of $120.00. The company's shares closed last Tuesday at $76.19, close to its 52-week low of $73.41. According to TipRanks.

Christine Brown on TipRanks | January 11, 2022

Read More 'STOK' Stories Here

STOK Price Returns

1-mo -24.77%
3-mo -38.35%
6-mo -51.85%
1-year -68.92%
3-year N/A
5-year N/A
YTD -49.60%
2021 -61.26%
2020 118.68%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6831 seconds.